SCHEMBL5432115

SCHEMBL5432115

O=C(O)c1ccc2[nH]cc(CCc3c[nH]c4ccc(C(=O)O)cc34)c2c1

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 3/20 0.82
HTR1A P08908 3/20 0.63
HTR1B P28222 3/20 0.63
HTR2C P28335 3/20 0.63
HSD17B10 Q99714 3/20 0.63
CYP1A2 P05177 3/20 0.63
TSHR P16473 3/20 0.63
HTR1D P28221 2/20 0.63
HTR5A P47898 2/20 0.63
HTR6 P50406 2/20 0.63
KMT2A Q03164 2/20 0.63
MEN1 O00255 1/20 0.63
TDP1 Q9NUW8 3/20 0.58
LMNA P02545 3/20 0.58
ADRA2A P08913 1/20 0.58
SLC6A2 P23975 1/20 0.58
HTR1E P28566 1/20 0.58
TMEM97 Q5BJF2 1/20 0.58
HPGD P15428 2/20 0.55
CYP2C19 P33261 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5432125 0.91 HTR7 (0.70) HTR7HTR1AHTR1BHTR2CHSD17B10
SCHEMBL4797436 0.91 HTR7 (1.00) HTR7HTR1AHTR1BHTR2CHSD17B10
SCHEMBL5929995 0.91 HTR7 (0.74) HTR7HTR1AHTR1BHTR2CHSD17B10
SCHEMBL38652005 0.91 HTR7 (0.74) HTR7HTR1AHTR1BHTR2CHSD17B10
SCHEMBL5424833 0.90 HTR7 (0.72) HTR7HTR1AHTR1BHTR2CHSD17B10
SCHEMBL4348714 0.89 HTR7 (0.72) HTR7HTR1AHTR1BHTR2CHSD17B10
Hydrochloric Acid SCHEMBL9448770 0.89 HTR7 (0.97) HTR7HTR1AHTR1BHTR2CHSD17B10
SCHEMBL8297284 0.88 HTR7 (0.70) HTR7HTR1AHTR1BHTR2CHSD17B10
SCHEMBL3347386 0.88 HTR7 (0.70) HTR7HTR1AHTR1BHTR2CHSD17B10
SCHEMBL9256337 0.88 HTR7 (0.70) HTR7HTR1AHTR1BHTR2CHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070015813-A1 Treatment of protein folding disorders QUEEN'S UNIVERSITY AT KINGSTON (CA) 2007-01-18 US claimed
US-20070015813-A1 Treatment of protein folding disorders QUEEN'S UNIVERSITY AT KINGSTON (CA) 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015813-A1 Treatment of protein folding disorders HSPA5, TTR, TUFM HTR7 1505/4885HTR1A 710/4885HTR1B 631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.